Stock ADAG ADAGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Adagene Inc. Stock

Equities

ADAG

US0053291078

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.8 USD +7.90% Intraday chart for Adagene Inc. +8.53% +44.97%
Mar. 29 Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 29 Adagene Inc. Announces Board Changes CI

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 124M
Net income 2024 * -49M Net income 2025 * -91M EV / Sales 2024 * -
Net cash position 2024 * 91.82M Net cash position 2025 * 22.83M EV / Sales 2025 * -
P/E ratio 2024 *
-3.18 x
P/E ratio 2025 *
-1.72 x
Employees 174
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.21%
More Fundamentals * Assessed data

Chart Adagene Inc.

Dynamic Chart

Latest news about Adagene Inc.

Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Adagene Inc. Announces Board Changes CI
Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board CI
ADRs Close Higher, Ambow Education Holding Ltd. Climbs 117.4% DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination MT
Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody CI
ADRs End Higher; The9 Climbs 16% DJ
Adagene Reports Positive Data on Colorectal Cancer Treatment Combination MT
Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium CI
ADRs End Lower; Aslan Pharmaceuticals Declines 38% DJ
ADRs Slump, Grifols S.A. Declines 14.0% DJ
ADRs Advance; Aslan Pharmaceuticals Climbs 27% DJ
ADRs End Lower; Secoo Holding Declines 28% DJ
ADRs Close Higher; Incannex Healthcare Inc. Climbs 723.7% DJ
More news

Analyst Recommendations on Adagene Inc.

Morgan Stanley Adjusts Price Target on Adagene to $5 From $7, Maintains Overweight Rating MT
HC Wainwright Starts Adagene at Buy With $5 Price Target MT
Morgan Stanley Cuts Price Target on Adagene to $7 From $15, Maintains Overweight Rating MT
Berenberg Emerging Biotech Conference FA
Morgan Stanley Adjusts Adagene's Price Target to $15 From $27, Reiterates Overweight Rating MT
More recommendations

Press releases Adagene Inc.

Adagene to Present at Investor Conferences in June GL
Adagene : Entry into Sales Agreement - Form 6-K PU
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update GL
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board GL
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 GL
More press releases

News in other languages on Adagene Inc.

LATE BRIEFING - Unternehmen und Märkte -2-
Sanofi : accord de licence avec la biotech chinoise Adagene
Sanofi zahlt Adagene in Entwicklungskooperation bis zu 2,5 Mrd USD
More news

Quotes and Performance

1 day+7.90%
1 week+8.53%
1 month+20.17%
3 months-14.63%
6 months+84.21%
Current year+44.97%
More quotes

Highs and lows

1 week
2.48
Extreme 2.48
2.80
1 month
2.01
Extreme 2.01
2.80
Current year
1.85
Extreme 1.8495
4.38
1 year
1.10
Extreme 1.1001
4.38
3 years
0.90
Extreme 0.9
20.98
5 years
0.90
Extreme 0.9
31.83
10 years
0.90
Extreme 0.9
31.83
More quotes

Managers and Directors - Adagene Inc.

Managers TitleAgeSince
Peizhi Luo CEO
 Chief Executive Officer 59 11-02-24
Man Kin Tam DFI
 Director of Finance/CFO 47 19-08-31
JC Xu CTO
 Chief Tech/Sci/R&D Officer 60 20-07-31
Members of the board TitleAgeSince
Peizhi Luo CEO
 Chief Executive Officer 59 11-02-24
Mervyn Turner BRD
 Director/Board Member 77 23-04-27
Cuong Viet Do BRD
 Director/Board Member 58 22-11-20
More insiders

Quotes

Date Price Change Volume
24-05-31 2.8 +7.90% 13,182
24-05-30 2.595 -1.70% 5,670
24-05-29 2.64 +4.35% 6,622
24-05-28 2.53 -1.94% 7,555
24-05-24 2.58 -7.53% 16,320

Delayed Quote Nasdaq, May 31, 2024 at 04:30 pm EDT

More quotes

Company Profile

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Sector
Biotechnology & Medical Research
Calendar
2024-06-05 - Jefferies Global Healthcare Conference
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.8 USD
Average target price
5 USD
Spread / Average Target
+78.57%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ADAGENE INC. Stock Adagene Inc.
+44.97% 124M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ADAG Stock